CANCER-IMMUNOTHERAPY - CURRENT STATUS OF TREATMENT WITH INTERLEUKIN-2 AND LYMPHOKINE-ACTIVATED KILLER CELLS

被引：23

作者：

VANHAELSTPISANI, CM

PISANI, RJ

KOVACH, JS

机构：

[1] MAYO CLIN & MAYO FDN,DEPT ONCOL,ROCHESTER,MN 55905

[2] MAYO CLIN & MAYO FDN,DIV THORAC DIS & INTERNAL MED,ROCHESTER,MN 55905

来源：

MAYO CLINIC PROCEEDINGS | 1989年 / 64卷 / 04期

关键词：

D O I：

10.1016/S0025-6196(12)65736-X

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：451 / 465

页数：15

共 115 条

[1] THE DEVELOPMENT OF ANTI-INTERLEUKIN-2 ANTIBODIES IN PATIENTS TREATED WITH RECOMBINANT HUMAN INTERLEUKIN-2 (IL-2) [J].

ALLEGRETTA, M ;

ATKINS, MB ;

DEMPSEY, RA ;

BRADLEY, EC ;

KONRAD, MW ;

CHILDS, A ;

WOLFE, SN ;

MIER, JW .

JOURNAL OF CLINICAL IMMUNOLOGY, 1986, 6 (06) :481-490

[2] PHASE-I EVALUATION OF RECOMBINANT INTERLEUKIN-2 IN PATIENTS WITH ADVANCED MALIGNANT DISEASE [J].

ATKINS, MB ;

GOULD, JA ;

ALLEGRETTA, M ;

LI, JJ ;

DEMPSEY, RA ;

RUDDERS, RA ;

PARKINSON, DR ;

REICHLIN, S ;

MIER, JW .

JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (09) :1380-1391

[3]

BARBA D, 1988, P AN M AM SOC CLIN, V7, P82

[4] EFFECTS OF INTERLEUKIN-2 ON RENAL-FUNCTION IN PATIENTS RECEIVING IMMUNOTHERAPY FOR ADVANCED CANCER [J].

BELLDEGRUN, A ;

WEBB, DE ;

AUSTIN, HA ;

STEINBERG, SM ;

WHITE, DE ;

LINEHAN, WM ;

ROSENBERG, SA .

ANNALS OF INTERNAL MEDICINE, 1987, 106 (06) :817-822

[5]

BELLDEGRUN A, 1988, CANCER RES, V48, P206

[6]

CHEEMA AR, 1972, CANCER, V29, P982, DOI 10.1002/1097-0142(197204)29:4<982::AID-CNCR2820290445>3.0.CO

[7]

2-#

[8] NONRESTRICTED CYTO-TOXICITY MEDIATED BY INTERLEUKIN-2-EXPANDED LEUKOCYTES IS INHIBITED BY ANTI-LFA-1 MONOCLONAL-ANTIBODIES (MOAB) BUT POTENTIATED BY ANTI-CD3 MOAB [J].

CHEN, BP ;

MALKOVSKY, M ;

HANK, JA ;

SONDEL, PM .

CELLULAR IMMUNOLOGY, 1987, 110 (02) :282-293

[9]

COHEN PJ, 1987, AM J PATHOL, V129, P208

[10]

COTRAN RS, 1988, J IMMUNOL, V140, P1883

← 1 2 3 4 5 6 7 8 9 10 →